Microbot Medical Inc. (MBOT) Key Metrics
MBOT valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $63.8M
- Enterprise value
- $26.2M
- P/E (TTM)
- —
- Forward P/E
- 31.7
- PEG ratio
- 0.70
- Price / sales
- 184.4
- Price / book
- 1.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.05
MBOT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMBOT valuation Price multiples at each fiscal year-end price.
MBOT returns How much profit the business earns on the capital it uses.
MBOT per-share figures Results divided by the shares outstanding at year-end.
MBOT financial health Debt, liquidity and how easily interest is covered.
MBOT efficiency & capital use Working capital cycle and where the cash goes.
MBOT valuation history
MBOT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MBOT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MBOT cash returned to shareholders
MBOT price vs earnings per share
MBOT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $91.6M | $17.5M | — | — | — | — | — | — | — | — |
| Enterprise value | $13.9M | $12.2M | — | — | — | — | — | — | — | — |
| Price / book | 1.2 | 5.0 | — | — | — | — | — | — | — | — |
| Earnings yield | −14.4% | −65.3% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −14.3% | −50.5% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.00 | $1.12 | $1.64 | $3.01 | $7.50 | $6.89 | $10.17 | $1.72 | $15.30 | $91.50 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.29 | −$0.73 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.28 | −$0.56 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.29 | −$0.57 | — | — | — | — | — | — | — | — |
| Cash per share | $1.72 | $0.35 | — | — | — | — | — | — | — | — |
| Book value per share | $1.69 | $0.23 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $1.69 | $0.23 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.02 | $0.01 | — | — | — | — | — | — | — | — |
| Shares outstanding | 45.8M | 15.6M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +192.7% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −32.4% | −285.0% | −182.2% | −121.5% | −58.5% | −32.8% | −44.1% | −128.6% | −130.2% | — |
| Return on invested capital (ROIC) | — | — | — | — | — | −884.3% | — | — | — | — |
| Return on assets (ROA) | −30.0% | −159.4% | −120.2% | −100.1% | −52.6% | −28.9% | −33.5% | −84.9% | −105.5% | −78.6% |
| Return on tangible assets | −16.1% | −189.7% | −129.0% | −138.1% | −67.5% | −34.9% | −19.5% | −119.2% | −68.9% | −286.9% |
| Financial health | ||||||||||
| Total debt | $865,000 | $111,000 | $231,000 | $462,000 | $680,000 | $813,000 | $903,000 | — | $0 | $76,000 |
| Cash & short-term investments | $78.6M | $5.5M | $6.4M | $8.3M | $15.5M | $24.6M | $31.3M | $5.2M | $10.8M | $2.7M |
| Net debt | −$77.7M | −$5.4M | −$6.2M | −$7.8M | −$14.8M | −$23.8M | −$30.4M | −$5.2M | −$10.8M | −$2.6M |
| Debt / equity | 0.01 | 0.03 | 0.05 | 0.06 | 0.05 | 0.03 | 0.03 | — | 0.00 | 0.04 |
| Debt / assets | 0.01 | 0.02 | 0.03 | 0.05 | 0.04 | 0.03 | 0.02 | — | 0.00 | 0.02 |
| Current ratio | 23.33 | 2.37 | 2.09 | 4.26 | 8.00 | 18.78 | 7.45 | 1.23 | 20.70 | 4.23 |
| Quick ratio | 23.16 | 2.37 | 2.10 | 4.31 | 8.09 | 18.78 | 7.99 | 1.23 | 20.56 | 4.23 |
| Interest coverage | — | — | — | -0.1 | -258.1 | -113.6 | -70.3 | — | -22.1 | -28.8 |
| Working capital | $76.4M | $3.4M | $4.1M | $6.7M | $13.9M | $23.9M | $31.1M | $1.1M | $10.4M | $2.5M |
| Invested capital | −$173,000 | −$1.8M | −$1.7M | −$528,000 | −$431,000 | $473,000 | $1.2M | −$3.9M | −$823,000 | −$937,000 |
| Tangible asset value | $77.6M | $3.5M | $4.5M | $7.3M | $14.4M | $24.3M | $31.5M | $1.3M | $10.0M | $1.7M |
| Net current asset value | $75.8M | $3.3M | $4.1M | $6.6M | $13.5M | $23.3M | $30.4M | $1.1M | $9.9M | $1.6M |
| Graham net-net per share | $1.64 | $0.20 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | — | $3,375 | $0 | — | $0 | $0 |
| Capex / depreciation | 1.28 | 0.27 | 0.31 | 0.82 | 0.91 | 1.34 | 2.57 | 4.13 | 2.76 | 2.50 |
| Efficiency | ||||||||||
| Days of inventory on hand | 2,267.7 | — | -249.6 | -495.6 | -429.8 | -7,050.4 | -11,393.2 | — | 634.4 | — |
| Days payables outstanding | 2,624.9 | 1,046.9 | 814.4 | 706.7 | 1,330.3 | 1,500.3 | 1,985.8 | 2,392.8 | 2,424.6 | 12,365.2 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.14 | 0.35 | 0.45 | 0.52 | 0.27 | 0.24 | 0.18 | 0.15 | 0.15 | 0.03 |
| Inventory turnover | 0.16 | — | — | — | — | — | — | — | 0.58 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $270,500 | $893,500 | $795,000 | $138,500 | $257,000 | $220,500 | $83,000 | $50,000 | $25,000 | $34,202 |
| Average payables | $338,000 | $261,000 | $236,500 | $197,500 | $277,000 | $279,500 | $457,000 | $354,000 | $139,500 | $338,772 |
| Average inventory | $292,000 | −$21,000 | −$72,500 | −$138,500 | −$89,500 | −$1.3M | −$2.6M | — | $36,500 | $1.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MBOT's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MBOT valuation and financial ratios
Microbot Medical earned a return on equity of −32.4% in fiscal 2025. It ended the year with $0.9 million of debt and $78.6 million in cash and short-term investments, a net cash position of $77.7 million.
See the MBOT income statement, the MBOT chart for price history, or the MBOT stock overview for the latest quote and news.
MBOT key metrics FAQ
What is Microbot Medical's return on equity?
Microbot Medical's return on equity (ROE) was −32.4% in fiscal 2025: net income of -$13.1 million on average shareholders' equity of $40.5 million.
How much debt does Microbot Medical have?
Microbot Medical had total debt of $0.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Microbot Medical's free cash flow yield?
Microbot Medical generated -$13.1 million of free cash flow in fiscal 2025, a free cash flow yield of −14.3% on its market value at year-end ($91.6 million).
What is Microbot Medical's current ratio?
Microbot Medical's current ratio was 23.33 at the end of fiscal 2025: current assets were 23.33 times current liabilities.